Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.49 |
| ▸ | PLK1 | P53350 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 6/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519106 | 0.90 | CHEK1 (0.52) | DYRK1ACHEK1PLK1BRD4CNR2 | |
| SCHEMBL6514411 | 0.82 | PLK1 (0.51) | CHEK1PLK1CNR2MAPT | |
| SCHEMBL6515626 | 0.82 | PLK1 (0.49) | DYRK1ACHEK1PLK1CNR2MAPT | |
| SCHEMBL6518373 | 0.81 | AURKA (0.47) | DYRK1ACHEK1PLK1CNR2KCNH2 | |
| SCHEMBL6508656 | 0.81 | AURKA (0.53) | CHEK1PLK1BRD4CNR2DRD2 | |
| Hydrochloric Acid SCHEMBL6515749 | 0.80 | CHEK1 (0.72) | DYRK1ACHEK1KCNH2MAPT | |
| SCHEMBL6515407 | 0.75 | CHEK1 (0.71) | CHEK1PLK1KCNH2 | |
| SCHEMBL6513772 | 0.75 | AKT1 (0.46) | PLK1BRD4 | |
| SCHEMBL6522395 | 0.75 | PLK1 (0.45) | DYRK1APLK1CNR2 | |
| SCHEMBL6522415 | 0.75 | CHEK1 (0.46) | DYRK1ACHEK1PLK1BRD4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | DYRK1A 1079/4885CHEK1 3/4885PLK1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.